American Journal of Hospice and Palliative Medicine®最新文献

{"title":"A doctor’s tears","authors":"Frederick Nenner","doi":"10.1177/104990910502200414","DOIUrl":"https://doi.org/10.1177/104990910502200414","url":null,"abstract":"","PeriodicalId":7716,"journal":{"name":"American Journal of Hospice and Palliative Medicine®","volume":"49 1","pages":"315 - 316"},"PeriodicalIF":0.0,"publicationDate":"2005-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79171218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospice news","authors":"","doi":"10.1177/104990910502200302","DOIUrl":"https://doi.org/10.1177/104990910502200302","url":null,"abstract":"","PeriodicalId":7716,"journal":{"name":"American Journal of Hospice and Palliative Medicine®","volume":"59 1","pages":"171 - 173"},"PeriodicalIF":0.0,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76938056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Call for manuscripts","authors":"","doi":"10.1177/104990910502200316","DOIUrl":"https://doi.org/10.1177/104990910502200316","url":null,"abstract":"","PeriodicalId":7716,"journal":{"name":"American Journal of Hospice and Palliative Medicine®","volume":"1 1","pages":"239 - 239"},"PeriodicalIF":0.0,"publicationDate":"2005-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90931427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Book Review: A Clinical Guide to Supportive and Palliative Care for HIV/AIDS","authors":"John W. Barnhill","doi":"10.1177/104990910502200216","DOIUrl":"https://doi.org/10.1177/104990910502200216","url":null,"abstract":"Multiple causes of abdominal pain occur in HIV/AIDS. Common ones include: • Gastrointestinal tract (GIT) spasm related to gastroenteritis • Pancreatitis (especially in patients on NRTIs) • Intra-abdominal lymphadenopathy (TB, lymphoma) • Kaposi’s sarcoma of the GIT (look for skin or mucosal lesions) • Sclerosing cholangitis (sometimes resulting in hepatitis and cholecystitis) • Gynaecological related pain (severe pelvic inflammatory disease, tuboovarian or pelvic abscesses) • Non-HIV-related causes (common surgical conditions like appendicitis) • Cytomegalovirus (CMV) • Herpetic ulcers","PeriodicalId":7716,"journal":{"name":"American Journal of Hospice and Palliative Medicine®","volume":"207 1","pages":"158 - 160"},"PeriodicalIF":0.0,"publicationDate":"2005-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73742147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospice news","authors":"","doi":"10.1177/104990910502200201","DOIUrl":"https://doi.org/10.1177/104990910502200201","url":null,"abstract":"In late December 2004, the Food and Drug Administration (FDA) approved ziconotide intrathecal (IT) infusion (Prialt®), Elan Corporation, Dublin, Ireland), for the management of severe pain in patients for whom IT therapy is warranted and who are intolerant or refractory to other treatment. Ziconotide is the first approved drug in a new class of nonopioid analgesics called N-type calcium channel blockers (NCCBs). A synthetic equivalent of a naturally occurring conopeptide found in a marine snail known as Conus magus, ziconotide selectively blocks calcium channels on nerves that ordinarily transmit pain signals to the brain. FDA approval was based on treatment of more than 1,200 patients and three phase-III clinical trials that evaluated its safety and efficacy in patients with severe chronic pain. The trials included a variety of subjects, including patients with pain related to failed back surgery, cancer, AIDS, and nonmalignant causes. Adverse side effects were mild to moderate and included dizziness, ataxia, confusion, and abnormal gait. For a fact sheet and prescribing information, visit Elan’s Web site at www.prialt.com. (Source: Medscape Medical News, January 15, 2005.)","PeriodicalId":7716,"journal":{"name":"American Journal of Hospice and Palliative Medicine®","volume":"22 1","pages":"87 - 89"},"PeriodicalIF":0.0,"publicationDate":"2005-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79548886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospice news","authors":"","doi":"10.1177/104990910502200102","DOIUrl":"https://doi.org/10.1177/104990910502200102","url":null,"abstract":"Research published in the November issue of the Journal of the National Cancer Institute reported that oncologists can safely give breast cancer patients radiation treatment and taxane drugs without increasing the risk of radiation pneumonitis. Radiation pneumonitis is an interstitial pulmonary inflammation that can develop in as many as 5 to 15 percent of patients with thoracic radiation treatment. Acute radiation pneumonitis occurs within one to six months following treatment. Symptoms can include low-grade fever, cough, and fullness in the chest. Severe reactions can result in dyspnea, pleuritic chest pain, hemoptysis, acute respiratory distress, and death. Fibrosis can occur without previous pneumonitis, but once pneumonitis occurs, fibrosis is almost certain to take place. The radiographic hallmark of radiation pneumonitis is a diffuse infiltrate corresponding to a previous radiation treatment field. According to a study conducted by Dr. Tse-Kuan Yu and colleagues at the University of Texas M. D. Anderson Cancer Center, new techniques for administering radiation therapy have made radiation-related pneumonitis much less common. However, there have been some recent reports that linked taxane chemotherapy in the increased risk of radiation-induced injury when used in conjunction with radiation treatment. The research team conducted a randomized study comparing paclitaxel-FAC (5-flurouracil, doxorubicin, and cyclophosphamide) with FAC alone in breast cancer patients, some of whom also underwent radiation therapy. The researchers analyzed these data to determine whether patients given the taxane drug had an increased risk of radiation-induced pneumonitis. The results of the study showed that patients with breast cancer treated with sequential paclitaxel, FAC, and radiation therapy appeared to have a very low rate of clinically relevant radiation pneumonitis that was no different from that of patients treated with FAC alone. In total, 5 percent of the 100 patients given paclitaxel developed pneumonitis compared with 4.5 percent of the 89 patients given FAC only. In the studies that found an increased risk, paclitaxel had been given just before or during radiation therapy. In the current study, patients received radiation three to four months after the end of paclitaxel treatment. The research team concluded that the risk of radiation pneumonitis should not be a determining factor in whether to use radiotherapy in conjunction with taxane drugs for breast cancer treatment. They agree that further research is necessary to explore the association between the risk of radiation pneumonitis and the combination of paclitaxel chemotherapy and radiation therapy. (Source: J Natl Cancer Inst. 2004; 96(22): 1676-1681.)","PeriodicalId":7716,"journal":{"name":"American Journal of Hospice and Palliative Medicine®","volume":"32 1","pages":"9 - 9"},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75169473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2004 Cumulative Subject Index","authors":"S. Baumrucker, G. Carter, Matt Stolick, Marie L Eloi-Stiven, Maria, Melissa S. Tobias, Madelon Finkel, Luisa, Lopez-Luciano, Vansantha, Kondamudi, M. Delarosa, M. Webb, Gary, Doolittle, E. Melton","doi":"10.1177/104990910502200116","DOIUrl":"https://doi.org/10.1177/104990910502200116","url":null,"abstract":"","PeriodicalId":7716,"journal":{"name":"American Journal of Hospice and Palliative Medicine®","volume":"25 1","pages":"74 - 78"},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79686178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2004 Cumulative Author Index","authors":"J. Chibnall, P. Duckro, T. Kannan, Seema Mishra, A. Singhal","doi":"10.1177/104990910502200115","DOIUrl":"https://doi.org/10.1177/104990910502200115","url":null,"abstract":"","PeriodicalId":7716,"journal":{"name":"American Journal of Hospice and Palliative Medicine®","volume":"53 1","pages":"69 - 73"},"PeriodicalIF":0.0,"publicationDate":"2005-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88400029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hospice news","authors":"","doi":"10.1177/104990910402100603","DOIUrl":"https://doi.org/10.1177/104990910402100603","url":null,"abstract":"Research published in the September 2004 issue of the Journal of Pain and Symptom Management reports that patients enrolled in hospice care cost Medicare less. The study, “Medicare Cost in Matched Hospice and NonHospice Cohorts,” also revealed that hospice patients lived longer, on average, than similar patients who did not choose hospice care. Commissioned by the National Hospice and Palliative Care Organization (NHPCO) and conducted by the actuarial firm of Milliman, USA, the study’s goal was to identify cost differences between patients who elect and do not elect to receive Medicare-paid hospice benefits. According to the research, the majority of patients with 16 of the most common terminal diagnoses who choose hospice care cost Medicare less. Cost savings range from $1,115 for rectal cancer patients to $8,879 for congestive heart failure patients. Researchers also found that, on average, hospice patients lived longer. These life spans range from 20 days for patients with a diagnosis of gallbladder cancer to 69 days for those with breast cancer. “With almost 30 percent of Medicare costs going for all types of care delivered towards the end of life, an understanding of the cost benefits of hospice is important,” said J. Donald Schumacher, president and CEO of NHPCO. “However, discussions relating to costs should never cloud the most important issue— hospice provides the highest quality of compassionate care for patients and families.” A significant factor in this study is the unique methodology used to work towards eliminating selection bias. Selection bias has been a recognized problem in previous studies contrasting hospice versus nonhospice patients. Medicare health insurance claims and enrollment data were used to measure both costs and time until death, starting from narrowly defined dates. Indicative markers were identified that represented unambiguous points in the end stage of each disease. This study began tracking patients further upstream in a manner that researchers suggest addresses many selection bias concerns. The data source was Medicare health insurance claims and enrollment data from 5 percent Sample Beneficiary Standard Analytic Files for years 1998, 1999, and 2000. This 5 percent sample is created by the Centers for Medicare & Medicaid Services as a statistically representative, longitudinal data set. The research includes 8,700 patients who met the criteria for this study. The article points out that a period of at least two to three months of hospice care may be optimal from both a cost and clinical standpoint. (Source: NHPCO press release, September 21, 2004.)","PeriodicalId":7716,"journal":{"name":"American Journal of Hospice and Palliative Medicine®","volume":"163 1","pages":"411 - 413"},"PeriodicalIF":0.0,"publicationDate":"2004-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73587909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Book Review: Living with Dying: A Handbook for End-of-Life Healthcare Practitioners","authors":"Francis C. Zanger","doi":"10.1177/104990910402100615","DOIUrl":"https://doi.org/10.1177/104990910402100615","url":null,"abstract":"","PeriodicalId":7716,"journal":{"name":"American Journal of Hospice and Palliative Medicine®","volume":"200 1","pages":"474 - 476"},"PeriodicalIF":0.0,"publicationDate":"2004-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73958283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}